Application and resistance mechanism of B-cell receptor signaling pathway inhibitors in lymphoma:reports from the 57th American Society of Hematology annual meeting
10.3760/cma.j.issn.1009-9921.2016.01.003
- VernacularTitle:B细胞受体信号通路抑制剂在淋巴瘤中的应用及耐药机制研究进展:第57届美国血液学会年会报道
- Author:
Wenjie XIONG
;
Lugui QIU
- Publication Type:Journal Article
- Keywords:
Lymphoma;
B-cell receptor signaling pathway inhibitors;
American Society of Hematology annual meeting
- From:
Journal of Leukemia & Lymphoma
2016;25(1):7-11
- CountryChina
- Language:Chinese
-
Abstract:
With the recent success of B-cell receptor (BCR) signaling pathway inhibitor in the treatment of patients with relapsed or refractory non-Hodgkin lymphoma (NHL), a number of new agents targeting the BCR signaling pathway are in a clinical research stage. In addition, multiple trials combining these agents with conventional cytotoxic chemotherapy, immunomodulatory agents, monoclonal antibodies, or other kinase inhibitors are underway. Studies have also found the drug resistance of BCR signaling pathway inhibitors, drawing attention of the mechanism and the way to overcome the drug resistance. Combined with the research progress reported in 57th American Society of Hematology (ASH) annual meeting, this article summarized the recent progress of BCR signaling pathway inhibitors and their resistance mechanism to provide new information on clinical therapy.
